XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Pfizer License Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
May 02, 2023
May 03, 2022
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Research and development expense     $ 19,330 $ 3,762   $ 46,440 $ 24,353  
Pfizer License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Upfront payment   $ 5,000            
Consideration transferred               $ 12,100
Royalty rate payment   15.00%            
Expected timing satisfaction, period   12 years            
Maximum payment on the timing of transaction   $ 20,000            
Pfizer License Agreement | Development and Regulatory Milestones                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contingent consideration, liability   128,000            
Pfizer License Agreement | Sales Milestones                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contingent consideration, liability   $ 525,000            
Series A Convertible Preferred Stock | Pfizer License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Shares issued under license agreement (in shares)   7,125,000            
Shares issued, price per share (usd per share)   $ 1.00            
Equity interest issued and issuable   $ 7,100            
Series A Convertible Preferred Stock                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Research and development expense         $ 8,800      
Series A Convertible Preferred Stock | Pfizer License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Shares issued under license agreement (in shares)   7,125,000            
Issuance of Series A convertible preferred stock pursuant to anti-dilution provision of license agreement with Pfizer Inc. (in shares) 8,823,529              
Research and development expense $ 8,800              
Series A Convertible Preferred Stock | Pfizer Inc. | Pfizer License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Interest percent   15.00%